Detailed Information

Cited 1 time in webofscience Cited 0 time in scopus
Metadata Downloads

Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic InhibitorCancer Patient Tissueoid with Self-Homing Nano-Targeting of Metabolic Inhibitor

Other Titles
Cancer Patient Tissueoid with Self-Homing Nano-Targeting of Metabolic Inhibitor
Authors
Yoon, Hyo‐JinChung, Young ShinLee, Yong JaeYu, Seung EunBaek, SewoomKim, Hye‐SeonKim, Sang WunLee, Jung-YunKim, SunghoonSung, Hak Joon
Issue Date
Nov-2021
Publisher
Wiley-VCH Verlag
Keywords
cancer cell-derived nanovesicles; ovarian cancer; patient-specific treatments; self-homing nano-targeting; tissueoid
Citation
Advanced Science, v.8, no.22, pp.2102640
Journal Title
Advanced Science
Volume
8
Number
22
Start Page
2102640
URI
https://yscholarhub.yonsei.ac.kr/handle/2021.sw.yonsei/5359
DOI
10.1002/advs.202102640
ISSN
2198-3844
Abstract
The current paradigm of cancer medicine focuses on patient- and/or cancer-specific treatments, which has led to continuous progress in the development of patient representatives (e.g., organoids) and cancer-targeting carriers for drug screening. As breakthrough concepts, i) living cancer tissues convey intact profiles of patient-specific microenvironmental signatures. ii) The growth mechanisms of cancer mass with intense cell-cell interactions can be harnessed to develop self-homing nano-targeting by using cancer cell-derived nanovesicles (CaNVs). Hence, a tissueoid model of ovarian cancer (OC) is developed by culturing OC patient tissues in a 3D gel chip, whose microchannel networks enable perfusion to maintain tissue viability. A novel model of systemic cancer responses is approached by xenografting OC tissueoids into ischaemic hindlimbs in nude mice. CaNVs are produced to carry general chemotherapeutics or new drugs under pre/clinical studies that target the BRCA mutation or energy metabolism, thereby increasing the test scope. This pioneer study cross-validates drug responses from the OC clinic, tissueoid, and animal model by demonstrating the alignment of results in drug type-specific efficiency, BRCA mutation-dependent drug efficiency, and metabolism inhibition-based anti-cancer effects. Hence, this study provides a directional foundation to accelerate the discovery of patient-specific drugs with CaNV application towards future precision medicine.
Files in This Item
There are no files associated with this item.
Appears in
Collections
ETC > 1. Journal Articles

qrcode

Items in Scholar Hub are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher KIM, HYESEON photo

KIM, HYESEON
College of Medicine
Read more

Altmetrics

Total Views & Downloads

BROWSE